Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH2101 in Smoldering Multiple Myeloma
NCT01222286Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Sep 2010
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IPH 2101 in smoldering multiple myeloma (SMM), sponsored by Innate Pharma. Started Sep 2010; status: completed.
02
Drugs
IPH 2101
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01222286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222286.